To dissect the underlying molecular mechanisms of adapted reactivation of the RTK/MAPK signaling in response to BRAF and combined BRAF/MEK inhibition, we conducted transcriptome gene profiling in vemurafenib-treated melanoma cells. This evidence concerns the gene MAP2K7 and melanoma.